Published in Obesity and Diabetes Week, April 24th, 2006
Arena recently received results from its chronic 12 and 6-month preclinical toxicology studies of APD356, its orally administered, internally discovered drug candidate for the treatment of obesity. The toxicology studies did not demonstrate any apparent drug effect on heart valves or pulmonary vasculature, and Arena continues to expect to initiate the APD356 phase III program in the second half of 2006.
"We are very encouraged by the results of these...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week